Baxter International Inc.

Análisis de la acción Baxter International Inc. (BAX)

$25.280

-0.470 (-1.86%)Al cierre

Loading chart…
Máximo
25.985
Apertura
25.950
Precio medio ponderado por volumen
25.47
Volumen
4.41M
Capitalización
17.08B
Mínimo
25.133
Importe
112.23M
EV/EBITDA, TTM
7.82

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.

www.baxter.com

Análisis de IA of Baxter International Inc. (BAX)

Comprar

Baxter International Inc is a good buy right now due to its current price of $25.28, which is below the average analyst price target of $27.67, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +29.64% and a recent 5-day change of +3.82%, suggesting positive momentum. However, the main risk is the negative net income reported in Q4 2024 at -$512 million, which reflects ongoing profitability challenges that investors should monitor closely.

Métricas de valoración

El PER previsto actual de Baxter International Inc. (BAX) es 11.57, frente a su media de 5 años de 13.85.

PER previsto

Valor razonable
Media 5A P/E
13.85
P/E actual
11.57
Sobrevalorada
17.41
Infravalorada
10.28

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
11.75
EV/EBITDA actual
7.82
Sobrevalorada
14.90
Infravalorada
8.60

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.48
P/S actual
1.12
Sobrevalorada
2.03
Infravalorada
0.94

Escenarios de precio de Alphio AI para BAX

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%BAX

$28.00

Precio del escenario

B

Base

Base · 50%BAX

$25.49

Precio del escenario

B

Bajista

Bajista · 25%BAX

$18.18

Precio del escenario

Ballenas con BAX en cartera

R

RWC Partners Limited

+ Con en carteraBAX

+8.80%

Rentabilidad a 3 meses

E

Edmond de Rothschild Asset Management (France)

+ Con en carteraBAX

+7.54%

Rentabilidad a 3 meses

P

Pzena Investment Management, Inc.

+ Con en carteraBAX

+6.58%

Rentabilidad a 3 meses

G

Greenhaven Associates Inc

+ Con en carteraBAX

+3.20%

Rentabilidad a 3 meses

F

First Pacific Advisors, LP

+ Con en carteraBAX

+0.94%

Rentabilidad a 3 meses

T

Tontine Management, LLC

+ Con en carteraBAX

-15.67%

Rentabilidad a 3 meses

Cronología de eventos

2026-08-19 (ET)

08:30:00

Baxter International Appoints John Rogers as CFO

2026-08-04 (ET)

09:00:00

Baxter International Launches Cash Tender Offers Up to $500M

2026-07-30 (ET)

09:00:00

Microsoft's Strong Earnings Boosts Stock Futures Rebound

07:30:00

Company Raises Full-Year Financial Outlook to $1.91

07:30:00

Baxter Reports Q2 Revenue of $2.96B, Exceeding Expectations

Noticias

Preguntas frecuentes sobre BAX, respondidas por Alphio AI

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Baxter International Inc is a good buy right now due to its current price of $25.28, which is below the average analyst price target of $27.67, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +29.64% and a recent 5-day change of +3.82%, suggesting positive momentum. However, the main risk is the negative net income reported in Q4 2024 at -$512 million, which reflects ongoing profitability challenges that investors should monitor closely.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar